Slide 1: Presentation Q3(19)
Presentation Q3(19) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea in brief
Headquarters & consumable production in Uppsala Q-linea in brief Introduction to the company Lead product ASTar® • Q-linea is developing disruptive solutions for faster infectious disease diagnostics Introduction to the company • First product is ASTar® with a initial focus on blood stream infection
Slide 4: Q-linea's lead product candidate – ASTar – a modular AST system
Q-linea’s lead product candidate – ASTar – a modular AST system • Phenotypic AST results in 3 to 6 hours for ASTar offering System Rapid blood • Answer <45 minutes for e.g. urine • Fully automated Simple to use • Up to 12 samples analyzed in parallel • Up to 50 samples per day1) Consumables Fully-au
Slide 5: ASTar key highlights vs. competition
ASTar key highlights vs. competition Disruptive AST analysis 1 Broadest panel coverage Enables both escalation & de-escalation Minimize need for follow-up tests required 2 Broad pathogen coverage Includes both fastidious & non-fastidious bacteria 3 High throughput & Random access Up to 50 patient sa
Slide 6: Key highlights third quarter
Key highlights third quarter Strengthening of our commercial organization in preparation for launch Thomas Fritz hired as Chief Commercial officer Positive feedback on our product offering Broad panel Broad MIC ranges Possible to handle many sample types Preparing for Health Economic (HEOR) Studies
Slide 7: Key highlights third quarter
Key highlights third quarter Received positive feedback from FDA on US study design Overall agreement on planned study design Q-linea can perform part of the study Reduced scope on specific fastidious bacteria New quality control analysis workflow All isolates needed for clinical study collected 40%
Slide 8: Key highlights third quarter
Key highlights third quarter Increased capacity for internal consumable production Optimized production workflow Access to new production facility in Uppsala Several ASTar systems under thorough testing Internal evaluation ongoing Have received latest instrument generation from Sanmina CE mark is fo
Slide 9: Income statement third quarter
Income statement third quarter • Net sales in the third quarter amounted to SEK 0.03 million (0.25). • Operating result totalled SEK -35.8 million (-29.8). • The company reported a loss after tax of SEK -35.1 million (-29.3). • Earnings per share amounted to SEK -1.53 (-1.98). Figures in parentheses
Slide 10: Balance sheet at third quarter end
Balance sheet at third quarter end • Cash and cash equivalents amounted to SEK 19.2 million (354.4) • Short-term investments in fixed-income funds 211.2 million (150.0). • Non-current assets, listed bonds SEK 151.8 million (0). Figures in parentheses refer to the outcome for the corresponding period
Slide 11: Cash flow statement third quarter
Cash flow statement third quarter • Cash flow from operating activities SEK -35.8 million (-31.2). • Cash flow from investing activities SEK 35.7 millions (30.0). • Cash flow from financing activities SEK -0.1 millions (-0.3). • Increased cash outflow from operating activities mainly due to a larger
Slide 12: Thank you
Thank you Strictly private and confidential 12